This study measures the safety and efficacy of repeated low dose MM-120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled trial.
This neuroimaging study (n=4) used positron emission tomography (PET) with a 5-HT2A receptor agonist radioligand (that would light up on scans) and cortical regions of interest (ROIs) to determine the regional occupancy of 5-HT2A receptors after oral administration of a psychoactive dose of psilocybin (10mg/70kg). Three areas with the greatest occupancy were within the default mode network (DMN). There was high variability across individuals.
This meta-analysis (2022) assessed patient-level data on the effects of psychedelics on suicidality across seven clinical trials. It was found that, relative to baseline, psychedelic therapy was associated with large effect sizes and sustained decreases in suicidality. The effect size was medium at 6 months was significant at all time points except 7-8 weeks.
This double-blind RCT (n=158) assessed 8 repeated doses of intravenous ketamine administered twice weekly at a low dose (0.2 mg/kg; n = 53), standard dose (0.5 mg/kg; n = 51) ketamine or placebo (n=54) in veterans and service members with PTSD. It was found that the standard dose of ketamine reduced MADRS scores significantly more than placebo. However, the trial failed to find a significant dose-related effect of ketamine on PTSD symptoms measured using the CAPS-5.
The Nordic Psychedelic Science Conference (NPSC) is the first conference specifically for the nordic countries. It will run from the 19th to the 21st of May 2022. Speakers include Ben Sessa, Ekaterina Malievskaia, David Erritzoe, and many more.
Northstar Council by Niko Whitefeather offers one-on-one preparation and integration, as well as sitting services for those who want to explore psychedelics.
Bipartisan members of Congress sent a letter requesting that the Drug Enforcement Administration (DEA) allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution.
Optimi Health Corp. has announced a second provisional patent for a proprietary two-part processing method that involves the extraction and transdermal delivery of psilocybin active components.
Luke Goldstein at The American Prospect explores the commercialization of psilocybin mushroom as part of their Rollups series.
Jennifer Mithcell at Scientific America explores how MDMA is being used to treat PTSD.